Peter Emtage

This inventor holds 15 USPTO granted patents and 7 published patent applications and 2 EPO patents. Top assignees: Cell Design Labs, Inc., Kite Pharma, Inc., Precigen, Inc.. Active years: 2021-2026.

USPTO Granted Patents = 15 (Patent Applications = 7)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 10)

Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 7(Granted Patents)

Location History:

Lafayette, CA (US) (2021 - 2024)
Germantown, MD (US) (2024)

Company Filing History:

7 out of 7

Cell Design Labs, Inc.

Years Active: 2021-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617825 - METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS (2026-05-05),

2. 12570958 - SINGLE- AND MULTI-CHAIN CHIMERIC ANTIGEN RECEPTORS (2026-03-10),

3. 12551530 - IMMUNE CELL FUNCTION (2026-02-17),

4. 12297243 - Methods and compositions for reducing the immunogenicity of chimeric notch receptors (2025-05-13),

5. 12280119 - Chimeric transmembrane proteins and uses thereof (2025-04-21),

6. 12180517 - Expression of novel cell tags (2024-12-31),

7. 12109235 - TGF-beta receptors and methods of use (2024-10-08),

8. 12065498 - Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same (2024-08-20),

9. 12060585 - Expression of novel cell tags (2024-08-13),

10. 11993660 - Chimeric polypeptides and methods of altering the membrane localization of the same (2024-05-28),

11. 11787848 - CD33 specific chimeric antigen receptors (2023-10-17),

12. 11708401 - Chimeric transmembrane proteins and uses thereof (2023-07-25),

13. 11325957 - Methods and compositions for reducing the immunogenicity of chimeric notch receptors (2022-05-10),

14. 11118168 - Expression of novel cell tags (2021-09-14),

15. 11111310 - Chimeric polypeptides and methods of altering the membrane localization of the same (2021-09-07),

Title: The Innovative Journey of Inventor Peter Emtage

Introduction

Peter Emtage is a prominent inventor based in Lafayette, California, recognized for his contributions to the field of biotechnology. With a total of 10 patents to his name, Emtage has made significant strides in the development of innovative technologies that enhance immunotherapeutic applications and improve cancer treatments.

Latest Patents

Emtage's latest patents reflect his commitment to advancing medical science. One of the notable inventions is related to the "Expression of novel cell tags," which discloses polynucleotides encoding cell tags intended for use in immunotherapeutic applications. This invention includes systems comprising polynucleotide cell tags designed to regulate the activity of genetically engineered cells in a subject.

Another significant patent is centered around "TGF-beta receptors and methods of use." This patent details engineered receptors involved in cytokine signaling. It focuses on modulating TGF-β signaling, methods for modulation, and the therapeutic potential of using chimeric antigen receptors to treat cancer.

Career Highlights

Throughout his career, Peter Emtage has worked with notable companies such as Cell Design Labs, Inc. and Precigen, Inc. His work has been paramount in bridging the gap between innovative research and practical applications in medicine.

Collaborations

Emtage has collaborated with esteemed colleagues such as Stephen Santoro and Ramya Yarlagadda, further fostering innovation in the biotechnology field. These collaborations have enhanced his work, leading to breakthroughs in treatment methodologies.

Conclusion

Peter Emtage exemplifies the spirit of innovation through his extensive work and numerous patents in the biotechnology sector. His commitment to improving medical treatments is evident in his latest inventions, making significant contributions to combating complex health challenges like cancer. With each patent, Emtage continues to pave the way for future innovations, demonstrating the vital role of inventors in advancing technology and health.